Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial

Gynecologic Oncology

Volumn 124, Issue 3, 2012, Pages 563-568

  Randall, Leslie M ^a   Sill, Michael W ^b,g   Burger, Robert A ^c   Monk, Bradley J ^d   Buening, Barbara ^e   Sorosky, Joel I ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f HARTFORD HOSPITAL   (United States)

^g UNIVERSITY AT BUFFALO   (United States)

Author keywords

Bevacizumab; CA 125; Ovarian cancer; Phase II trial; Response assessment

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; FEMALE; GYNECOLOGIC CANCER INTERGROUP CRITERIA; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RADIOGRAPHIC EVALUATION CRITERIA IN SOLID TUMOR; RECURRENT CANCER; RETROSPECTIVE STUDY; SCORING SYSTEM;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CA-125 ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 84856758922     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.11.035     Document Type: Article

References (26)

1. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
2. G.J. Rustin, P. Timmers, A. Nelstrop, G. Shreeves, S.M. Bentzen, and B. Baron Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide J Clin Oncol 24 2006 45 51
3. G.J. Rustin, M. Marples, A.E. Nelstrop, M. Mahmoudi, and T. Meyer Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels J Clin Oncol 19 2001 4054 4057
4. G.J. Rustin, A.E. Nelstrop, M.K. Tuxen, and H.E. Lambert Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study Ann Oncol 7 1996 361 364
5. G.J. Rustin, M. Quinn, T. Thigpen, A. du Bois, E. Pujade-Lauraine, and A. Jakobsen Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) J Natl Cancer Inst 96 2004 487 488
6. I. Vergote, G.J. Rustin, E.A. Eisenhauer, G.B. Kristensen, E. Pujade-Lauraine, and M.K. Parmar Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup J Natl Cancer Inst 92 2000 1534 1535
7. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 5165 5171
8. M. Buyse, and P. Piedbois On the relationship between response to treatment and survival time Stat Med 15 1996 2797 2812
9. J. Crowley, and M. Hu Covariance analysis of heart transplant survival data J Am Stat Assoc 72 1977 27 36
10. N. Mantel, and D.P. Byar Evaluation of response-time data involving transient states: an illustration using heart-transplant data J Am Stat Assoc 69 1974 81 86
11. J.R. Anderson, K.C. Cain, and R.D. Gelber Analysis of survival by tumor response J Clin Oncol 1 1983 710 719
12. M.G. Kendall The treatment of ties in rank problems Biometrika 33 1945 239 251
13. R.C. Bast, J.T. Thigpen, S.G. Arbuck, K. Basen-Engquist, and L.B. Burke Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop Gynecol Oncol 107 2007 173 176
14. N.S. Azad, C.M. Annunziata, S.M. Steinberg, L. Minasian, A. Premkumar, and C. Chow Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy Cancer 112 2008 1726 1732
15. S. Kang, S.S. Seo, and S.Y. Park Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer J Surg Oncol 100 2009 244 247
16. K.K. Zorn, C. Tian, W.P. McGuire, W.J. Hoskins, M. Markman, and F.M. Muggia The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study Cancer 115 2009 1028 1035
17. G. Ferrandina, M. Ludovisi, G. Corrado, V. Carone, M. Petrillo, and G. Scambia Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer Gynecol Oncol 109 2008 187 193
18. A. Prat, M. Parera, S. Peralta, M.A. Perez-Benavente, A. Garcia, and A. Gil-Moreno Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer Ann Oncol 19 2008 327 331
19. J.M. Riedinger, J. Wafflart, G. Ricolleau, N. Eche, H. Larbre, and J.P. Basuyau CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study Ann Oncol 17 2006 1234 1238
20. B. Gronlund, C. Høgdall, J. Hilden, S.A. Engelholm, E.V. Høgdall, and H.H. Hansen Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second line chemotherapy of ovarian carcinoma? J Clin Oncol 22 2004 4051 4058
21. A. Gadducci, S. Cosio, A. Fanucchi, S. Negri, R. Cristofani, and A.R. Genazzani The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma Gynecol Oncol 93 2004 131 136
22. R.E. Hawkins, K. Roberts, E. Wiltshaw, J. Mundy, I.J. Fryatt, and V.R. McCready The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma Br J Obstet Gynaecol 96 1989 1395 1399
23. T. Högberg, and B. Kågedal Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma Acta Obstet Gynecol Scand 69 1990 423 429
24. P.M. Fayers, G. Rustin, R. Wood, A. Nelstrop, R.C. Leonard, and P. Wilkinson The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer Int J Gynecol Cancer 3 1993 285 292
25. V.J. Hunter, L. Daly, M. Helms, J.T. Soper, A. Berchuck, and D.L. Clarke-Pearson The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction Am J Obstet Gynecol 163 1990 1164 1167
26. G.J. Rustin, J.N. Gennings, A.E. Nelstrop, H. Covarrubias, H.E. Lambert, and K.D. Bagshawe Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group J Clin Oncol 7 1989 1667 1671